查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1544599

僵直性脊椎炎市场、机会、成长动力、产业趋势分析与预测，2024-2032

Ankylosing Spondylitis Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 220 Pages | 商品交期: 2-3个工作天内

价格
简介目录

由于人们对僵直性脊椎炎的认识和诊断的提高，以及治疗方案的进步，预计 2024 年至 2032 年间，僵直性脊椎炎的市场规模将以 8.2% 的复合年增长率增长。影像技术和生物标记发现的创新促进了更早、更精确的诊断，从而增加了对专业治疗和管理策略的需求。

僵直性脊椎炎（AS）盛行率的上升和患者群体的扩大也推动了市场的成长。报告显示，僵直性脊椎炎影响全球 0.1% 至 1.4% 的人口。随着遗传和环境因素导致 AS 发病率不断增加，对有效治疗解决方案和管理策略的需求不断增加。此外，研发投资的增加以及新治疗方法正在进行的临床试验正在促进创新药物和治疗方式的创造。

本行业分为治疗、给药途径、类型、应用、配销通路和地区。

根据治疗，由于皮质类固醇在减轻发炎和控制僵直性脊椎炎相关症状方面的功效已被证明，皮质类固醇领域的僵直性脊椎炎市场规模预计将在 2024 年至 2032 年间增长。皮质类固醇不仅可以迅速缓解疼痛和肿胀，提高患者的活动能力和整体生活质量，而且在控制急性发作和调节免疫反应方面发挥关键作用，从而显着增加了他们的需求。

从 2024 年到 2032 年，青少年应用领域的 AS 市场预计将出现显着的复合年增长率。患有早发性 AS 的青少年通常表现出独特的临床特征，如果不及时干预，就会面临更严重的后果。这一现实强调了对专门护理和量身定制的治疗策略的需求，以满足年轻患者的独特需求。

亚太地区僵直性脊椎炎产业预计从 2024 年到 2032 年将出现显着增长。先进诊断设备的激增，加上专门的治疗中心，不仅有利于早期诊断，而且可以确保有效的管理，促进区域市场的扩张。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 僵直性脊椎炎盛行率增加
      • 治疗方案的进步
      • 医疗保健支出增加
    • 产业陷阱与挑战
      • 与药物相关的副作用
  • 成长潜力分析
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按处理方式，2021 - 2032 年

  • 主要趋势
  • 非类固醇类抗发炎药（NSAID）
  • 生物疗法
    • 肿瘤坏死因子抑制剂
    • IL-17抑制剂
  • JAK抑制剂
  • 缓解病情抗风湿药物 (DMARD)
  • 皮质类固醇

第 6 章：市场估计与预测：按管理途径，2021 年至 2032 年

  • 主要趋势
  • 注射用
  • 口服

第 7 章：市场估计与预测：按类型，2021 - 2032

  • 主要趋势
  • 处方药
  • 非处方药

第 8 章：市场估计与预测：按应用分类，2021 - 2032

  • 主要趋势
  • 成年人
  • 少年

第 9 章：市场估计与预测：按配销通路划分，2021 - 2032 年

  • 主要趋势
  • 医院药房
  • 零售药局
  • 网路药局

第 10 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 11 章：公司简介

  • AbbVie, Inc.
  • Amgen, Inc.
  • Bayer AG
  • Eli Lilly and Company
  • Horizon Pharma
  • Janssen Biotech, Inc.
  • Merck and Co., Inc.
  • Novartis AG
  • PRIMUS PHARMACEUTICALS
  • Pfizer, Inc.
  • Sandoz Group AG
  • UCB, Inc.
简介目录
Product Code: 10134

Ankylosing spondylitis market size is anticipated to grow at an 8.2% CAGR between 2024 and 2032 driven by increasing awareness and diagnosis of the condition, coupled with advancements in treatment options. Innovations in imaging technologies and biomarker discoveries have facilitated earlier and more precise diagnoses, subsequently boosting the demand for specialized treatments and management strategies.

The market growth is also propelled by the rising prevalence of ankylosing spondylitis (AS) and an expanding patient demographic. Reports indicate that ankylosing spondylitis affects between 0.1% to 1.4% of the global population. As genetic and environmental factors drive the increasing incidence of AS, the demand for effective treatment solutions and management strategies intensifies. Moreover, heightened investments in R and D, alongside ongoing clinical trials for new therapeutic methods, are catalyzing the creation of innovative drugs and treatment modalities.

The industry is classified into treatment, route of administration, type, application, distribution channel, and region.

Based on treatment, the ankylosing spondylitis market size from the corticosteroids segment is poised to grow between 2024 and 2032 due to their proven efficacy in alleviating inflammation and managing AS-related symptoms. Corticosteroids not only offer swift relief from pain and swelling, enhancing patient mobility and overall quality of life but also play a pivotal role in controlling acute flare-ups and modulating immune responses, significantly boosting their demand.

AS market from the juvenile application segment is set to witness a significant CAGR from 2024 to 2032. This is driven by the rising acknowledgment and diagnosis of the disease in younger demographics, notably children and adolescents. Juveniles with early-onset AS often exhibit unique clinical features and face graver outcomes without timely intervention. This reality underscores the demand for specialized care and tailored treatment strategies that cater to the distinct needs of younger patients.

Asia Pacific ankylosing spondylitis industry is expected to accrue notable growth from 2024 to 2032. The growth is attributed to enhancements in healthcare infrastructure and a growing awareness of inflammatory diseases. The proliferation of advanced diagnostic facilities, coupled with specialized treatment centers, not only facilitates early diagnosis but also ensures effective management, bolstering the regional market expansion.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of ankylosing spondylitis
      • 3.2.1.2 Advancements in treatment options
      • 3.2.1.3 Rising healthcare expenditure
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Side effects associated with the medications
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Non-steroidal anti-inflammatory drugs (NSAIDs)
  • 5.3 Biologic therapies
    • 5.3.1 TNF inhibitors
    • 5.3.2 IL-17 inhibitors
  • 5.4 JAK Inhibitors
  • 5.5 Disease-modifying anti-rheumatic drugs (DMARDs)
  • 5.6 Corticosteroids

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Parenteral
  • 6.3 Oral

Chapter 7 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Prescription drugs
  • 7.3 OTC drugs

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Adults
  • 8.3 Juveniles

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Hospital pharmacies
  • 9.3 Retail pharmacies
  • 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Netherlands
    • 10.3.7 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
    • 10.4.6 Rest of Asia Pacific
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Rest of Latin America
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 UAE
    • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

  • 11.1 AbbVie, Inc.
  • 11.2 Amgen, Inc.
  • 11.3 Bayer AG
  • 11.4 Eli Lilly and Company
  • 11.5 Horizon Pharma
  • 11.6 Janssen Biotech, Inc.
  • 11.7 Merck and Co., Inc.
  • 11.8 Novartis AG
  • 11.9 PRIMUS PHARMACEUTICALS
  • 11.10 Pfizer, Inc.
  • 11.11 Sandoz Group AG
  • 11.12 UCB, Inc.